Puma Bio to adjust proposed labeling for neratinib after meeting with CHMP oncology advisory group; shares up 2% after hours By Seeking Alpha
Puma Biotechnology
Puma sells commercialization rights to Nerlynx in Latin America
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | FiercePharma
Puma Biotechnology
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
Knight Therapeutics licences cancer drug from Puma Biotechnology
Puma Biotech: Wounded Predator Ready To Jump Back (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology | Business Wire
Puma Biotechnology enters into a collaborative agreement with Strata Oncology
Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting
Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) | Business Wire
Puma Biotechnology
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
PUMA is a cellular target of miR-BART5. (A) Target site of miR-BART5 in... | Download Scientific Diagram
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Puma Logo clipart - Blue, Text, Font, transparent clip art
Puma Biotechnology
Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
Press Releases — Strata Oncology
PDF) Off-patent oral oncology drugs for kids (O3K FP7-project): from bedside to PUMA
3 Stocks Tumbling This Month: Clovis Oncology, Hyperion Therapeutics, and Puma Biotechnology - San Antonio Express-News
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today | The Motley Fool
Puma Biotechnology
